NasdaqGS - Nasdaq Real Time Price • USD
Regeneron Pharmaceuticals, Inc. (REGN)
At close: May 10 at 4:00 PM EDT
After hours: May 10 at 6:27 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 23 | 23 | 24 | 24 |
| Avg. Estimate | 10.63 | 11.89 | 44.2 | 47.87 |
| Low Estimate | 9.27 | 10.4 | 39.87 | 40.97 |
| High Estimate | 12.86 | 14.31 | 51.53 | 61.37 |
| Year Ago EPS | 10.24 | 11.59 | 43.79 | 44.2 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 20 | 19 | 24 | 24 |
| Avg. Estimate | 3.38B | 3.56B | 13.85B | 14.97B |
| Low Estimate | 3.15B | 3.34B | 13.29B | 13.92B |
| High Estimate | 3.5B | 3.75B | 14.42B | 16.86B |
| Year Ago Sales | -- | 3.36B | 13.12B | 13.85B |
| Sales Growth (year/est) | -- | 5.80% | 5.60% | 8.10% |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | 9.84 | 10.72 | 10.73 | 10.09 |
| EPS Actual | 10.24 | 11.59 | 11.86 | 9.55 |
| Difference | 0.4 | 0.87 | 1.13 | -0.54 |
| Surprise % | 4.10% | 8.10% | 10.50% | -5.40% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 10.63 | 11.89 | 44.2 | 47.87 |
| 7 Days Ago | 10.87 | 12.05 | 44.71 | 47.54 |
| 30 Days Ago | 11.02 | 12.02 | 45.03 | 47.54 |
| 60 Days Ago | 10.95 | 11.85 | 44.65 | 47.19 |
| 90 Days Ago | 11.06 | 11.9 | 44.91 | 47.09 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | 2 | 2 | 3 |
| Up Last 30 Days | 4 | 6 | 7 | 12 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 7 | 7 | 7 | 5 |
Growth Estimates
| CURRENCY IN USD | REGN | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 3.80% | -- | -- | 8.40% |
| Next Qtr. | 2.60% | -- | -- | 11.90% |
| Current Year | 0.90% | -- | -- | 5.60% |
| Next Year | 8.30% | -- | -- | 13.00% |
| Next 5 Years (per annum) | 9.90% | -- | -- | 11.05% |
| Past 5 Years (per annum) | 14.67% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | Cantor Fitzgerald: Neutral to Neutral | 5/3/2024 |
| Maintains | TD Cowen: Buy to Buy | 4/24/2024 |
| Reiterates | Cantor Fitzgerald: Neutral to Neutral | 4/17/2024 |
| Maintains | UBS: Buy to Buy | 4/17/2024 |
| Reiterates | Cantor Fitzgerald: Neutral to Neutral | 4/15/2024 |
| Maintains | B of A Securities: Underperform to Underperform | 4/12/2024 |
Related Tickers
VRTX Vertex Pharmaceuticals Incorporated
422.78
+0.90%
CRSP CRISPR Therapeutics AG
51.17
-4.44%
MDGL Madrigal Pharmaceuticals, Inc.
205.25
-0.81%
NTLA Intellia Therapeutics, Inc.
24.46
-1.61%
SRPT Sarepta Therapeutics, Inc.
131.82
-0.36%
ALNY Alnylam Pharmaceuticals, Inc.
150.47
-0.59%
BNTX BioNTech SE
91.67
-0.42%
BMRN BioMarin Pharmaceutical Inc.
81.03
-0.84%
MRNA Moderna, Inc.
117.31
-4.39%
VKTX Viking Therapeutics, Inc.
73.64
-8.18%